Advanced search
Publication Cover
Cancer Investigation Volume 28, 2010 - Issue 7
Submit an article Journal homepage
452
Views
35
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLEImaging, Diagnosis, Prognosis

Immune Signatures Predict Prognosis in Localized Cancer

David S HsuDuke Institute for Genome Sciences and Policy, Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Urology and Immunology, Johns Hopkins SKCCC, Baltimore, Maryland, USA, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
,
Mickey K KimDuke Institute for Genome Sciences and Policy, Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Urology and Immunology, Johns Hopkins SKCCC, Baltimore, Maryland, USA, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
,
Bala S. BalakumaranDuke Institute for Genome Sciences and Policy, Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Urology and Immunology, Johns Hopkins SKCCC, Baltimore, Maryland, USA, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
,
Chaitanya R AcharyaDuke Institute for Genome Sciences and Policy, Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Urology and Immunology, Johns Hopkins SKCCC, Baltimore, Maryland, USA, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
,
Carey K AndersDuke Institute for Genome Sciences and Policy, Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Urology and Immunology, Johns Hopkins SKCCC, Baltimore, Maryland, USA, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
,
Tim ClayDuke Institute for Genome Sciences and Policy, Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Urology and Immunology, Johns Hopkins SKCCC, Baltimore, Maryland, USA, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
,
H. Kim LyerlyDuke Institute for Genome Sciences and Policy, Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Urology and Immunology, Johns Hopkins SKCCC, Baltimore, Maryland, USA, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
,
Charles G. DrakeDuke Institute for Genome Sciences and Policy, Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Urology and Immunology, Johns Hopkins SKCCC, Baltimore, Maryland, USA, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
,
Michael A. MorseDuke Institute for Genome Sciences and Policy, Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Urology and Immunology, Johns Hopkins SKCCC, Baltimore, Maryland, USA, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
&
Phillip G. FebboDuke Institute for Genome Sciences and Policy, Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA, Division of Medical Oncology, Urology and Immunology, Johns Hopkins SKCCC, Baltimore, Maryland, USA, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
 show all
Pages 765-773 | Published online: 22 Jun 2010

REFERENCES

  • Balkwill, F.; Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 2001, 357, 539–545.
  • Clemente, C.G.; Mihm, M.C., Jr.; Bufalino, R.; Zurrida, S.; Collini, P.; Cascinelli, N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77, 1303–1310.
  • Coca, S.; Perez-Piqueras, J.; Martinez, D.; Colmenarejo, A.; Saez, M.A.; Vallejo, C.; Martos, J.A.; Moreno, M. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997, 79, 2320–2328.
  • Diederichsen, A.C.; Hjelmborg, J.B.; Christensen, P.B.; Zeuthen, J.; Fenger, C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother 2003, 52, 423–428.
  • Ishigami, S.; Natsugoe, S.; Tokuda, K.; Nakajo, A.; Che, X.; Iwashige, H.; Aridome, K.; Hokita, S.; Aikou, T. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000, 88, 577–583.
  • Imada, A.; Shijubo, N.; Kojima, H.; Abe, S. Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Respir J 2000, 15, 1087–1093.
  • Leek, R.D.; Landers, R.J.; Harris, A.L.; Lewis, C.E. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 1999, 79, 991–995.
  • Leek, R.D.; Lewis, C.E.; Whitehouse, R.; Greenall, M.; Clarke, J.; Harris, A.L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996, 56, 4625–4629.
  • Ribatti, D.; Ennas, M.G.; Vacca, A.; Ferreli, F.; Nico, B.; Orru, S.; Sirigu, P. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest 2003, 33, 420–425.
  • Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature 2002, 420, 860–867.
  • Pollard, J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4, 71–78.
  • Galon, J.; Costes, A.; Sanchez-Cabo, F.; Kirilovsky, A.; Mlecnik, B.; Lagorce-Pages, C.; Tosolini, M.; Camus, M.; Berger, A.; Wind, P.; Zinzindohoue, F.; Bruneval, P.; Cugnenc, P.H.; Trajanoski, Z.; Fridman, W.H.; Pages, F. Type density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313, 1960–1964.
  • Chin, K.; DeVries, S.; Fridlyand, J.; Spellman, P.T.; Roydasgupta, R.; Kuo, W.L.; Lapuk, A.; Neve, R.M.; Qian, Z.; Ryder, T.; Chen, F.; Feiler, H.; Tokuyasu, T.; Kingsley, C.; Dairkee, S.; Meng, Z.; Chew, K.; Pinkel, D.; Jain, A.; Ljung, B.M.; Esserman, L.; Albertson, D.G.; Waldman, F.M.; Gray, J.W. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10, 529–541.
  • Wang, Y.; Klijn, J.G.; Zhang, Y.; Sieuwerts, A.M.; Look, M.P.; Yang, F.; Talantov, D.; Timmermans, M.; Meijer-van Gelder, M.E.; Yu, J.; Jatkoe, T.; Berns, E.M.; Atkins, D.; Foekens, J.A. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365, 671–679.
  • Miller, L.D.; Smeds, J.; George, J.; Vega, V.B.; Vergara, L.; Ploner, A.; Pawitan, Y.; Hall, P.; Klaar, S.; Liu, E.T.; Bergh, J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005, 102, 13550–13555.
  • Glinsky, G.V.; Glinskii, A.B.; Stephenson, A.J.; Hoffman, R.M.; Gerald, W.L. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004, 113, 913–923.
  • Savage, K.J.; Monti, S.; Kutok, J.L.; Cattoretti, G.; Neuberg, D.; De Leval, L.; Kurtin, P.; Dal Cin, P.; Ladd, C.; Feuerhake, F.; Aguiar, R.C.; Li, S.; Salles, G.; Berger, F.; Jing, W.; Pinkus, G.S.; Habermann, T.; Dalla-Favera, R.; Harris, N.L.; Aster, J.C.; Golub, T.R.; Shipp, M.A. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003, 102, 3871–3879.
  • Potti, A.; Mukherjee, S.; Petersen, R.; Dressman, H.K.; Bild, A.; Koontz, J.; Kratzke, R.; Watson, M.A.; Kelley, M.; Ginsburg, G.S.; West, M.; Harpole, D.H., Jr.; Nevins, J. R. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006, 355, 570–580.
  • Horvath, S.; Zhang, B.; Carlson, M.; Lu, K.V.; Zhu, S.; Felciano, R.M.; Laurance, M.F.; Zhao, W.; Qi, S.; Chen, Z.; Lee, Y.; Scheck, A.C.; Liau, L.M.; Wu, H.; Geschwind, D.H.; Febbo, P.G.; Kornblum, H.I.; Cloughesy, T.F.; Nelson, S.F.; Mischel, P.S. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci USA 2006, 103, 17402–17407.
  • Golub, T.R.; Slonim, D.K.; Tamayo, P.; Huard, C.; Gaasenbeek, M.; Mesirov, J.P.; Coller, H.; Loh, M.L.; Downing, J.R.; Caligiuri, M.A.; Bloomfield, C.D.; Lander, E.S. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286, 531–537.
  • De Visser, K.E.; Eichten, A.; Coussens, L.M. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6, 24–37.
  • Anders, C.K.; Acharya, C.R.; Hsu, D.S.; Broadwater, G.; Garman, K.; Foekens, J.A.; Zhang, Y.; Wang, Y.; Marcom, K.; Marks, J.R.; Mukherjee, S.; Nevins, J.R.; Blackwell, K.L.; Potti, A. Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS ONE 2008, 3, e1373.
  • Mantovani, A.; Bonecchi, R.; Locati, M. Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat Rev Immunol 2006, 6, 907–918.
  • Bingle, L.; Brown, N.J.; Lewis, CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002, 196, 254–265.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.